Stay updated with breaking news from Nasdaq Bcab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BioAtla, Inc. (NASDAQ:BCAB – Get Rating) insider Christian Vasquez purchased 14,152 shares of the company’s stock in a transaction that occurred on Tuesday, June 7th. The stock was bought at an average cost of $3.04 per share, for a total transaction of $43,022.08. Following the purchase, the insider now directly owns 38,677 shares in the […]
BioAtla (NASDAQ:BCAB – Get Rating) and Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership. Earnings & Valuation This table compares BioAtla and Tarsus Pharmaceuticals’ […]
BioAtla (NASDAQ:BCAB – Get Rating) is one of 252 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare BioAtla to similar businesses based on the strength of its analyst recommendations, dividends, risk, profitability, valuation, institutional ownership and earnings. Institutional & Insider Ownership 70.6% of […]
BioAtla (NASDAQ:BCAB – Get Rating) is one of 252 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare BioAtla to related businesses based on the strength of its earnings, profitability, institutional ownership, risk, analyst recommendations, valuation and dividends. Insider and Institutional Ownership 70.6% of […]
UBS Asset Management Americas Inc. purchased a new stake in BioAtla, Inc. (NASDAQ:BCAB – Get Rating) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 8,638 shares of the company’s stock, valued at approximately $254,000. Several other large investors have also […]